Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai Foresees Tepid Growth for Next 3 Years: New Biz Plan
Chugai Pharmaceutical predicts only a low-single-digit compound annual growth rate not exceeding the 3% range for the next three years on a core EPS basis, according to its 2016-2018 business plan unveiled on January 28. “It will be difficult to…
To read the full story
Related Article
- Chugai Positions Mid-Sized Molecule Drugs as Third Pillar of Business, Aims to Produce First Candidate within 3 Years
February 1, 2016
- Kadcyla Development for Gastric Cancer Discontinued: Chugai
January 29, 2016
- Chugai Delivers Record Earnings, but Pegasys Falters on IFN-Free Hep C Therapies
January 29, 2016
BUSINESS
- Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
- ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
February 18, 2026
- Asahi Kasei Gets Global Rights to Alchemedicine’s Lead Compounds
February 18, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…